336 related articles for article (PubMed ID: 30830270)
21. Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis.
Handa P; Vemulakonda AL; Maliken BD; Morgan-Stevenson V; Nelson JE; Dhillon BK; Hennessey KA; Gupta R; Yeh MM; Kowdley KV
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):77-85. PubMed ID: 28051796
[TBL] [Abstract][Full Text] [Related]
22. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.
Coilly A; Desterke C; Guettier C; Samuel D; Chiappini F
Sci Rep; 2019 Dec; 9(1):19785. PubMed ID: 31874999
[TBL] [Abstract][Full Text] [Related]
23. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
Ogawa K; Kobayashi T; Furukawa JI; Hanamatsu H; Nakamura A; Suzuki K; Kawagishi N; Ohara M; Umemura M; Nakai M; Sho T; Suda G; Morikawa K; Baba M; Furuya K; Terashita K; Kobayashi T; Onodera M; Horimoto T; Shinada K; Tsunematsu S; Tsunematsu I; Meguro T; Mitsuhashi T; Hato M; Higashino K; Shinohara Y; Sakamoto N
Sci Rep; 2020 Jan; 10(1):321. PubMed ID: 31941930
[TBL] [Abstract][Full Text] [Related]
24. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
25. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH.
Del Ben M; Overi D; Polimeni L; Carpino G; Labbadia G; Baratta F; Pastori D; Noce V; Gaudio E; Angelico F; Mancone C
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463024
[TBL] [Abstract][Full Text] [Related]
27. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
[TBL] [Abstract][Full Text] [Related]
28. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis.
Kurbatova IV; Topchieva LV; Dudanova OP; Shipovskaya AA
Ter Arkh; 2019 May; 91(4):21-27. PubMed ID: 31094472
[TBL] [Abstract][Full Text] [Related]
30. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
Mayo R; Crespo J; Martínez-Arranz I; Banales JM; Arias M; Mincholé I; Aller de la Fuente R; Jimenez-Agüero R; Alonso C; de Luis DA; Vitek L; Stritesky J; Caballería J; Romero-Gómez M; Martín-Duce A; Mugüerza Huguet JM; Busteros-Moraza JI; Idowu MO; Castro A; Martínez-Chantar ML; Ortiz P; Bruha R; Lu SC; Bedossa P; Noureddin M; Sanyal AJ; Mato JM
Hepatol Commun; 2018 Jul; 2(7):807-820. PubMed ID: 30027139
[TBL] [Abstract][Full Text] [Related]
31. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
32. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Singh S; Allen AM; Wang Z; Prokop LJ; Murad MH; Loomba R
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):643-54.e1-9; quiz e39-40. PubMed ID: 24768810
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression.
Fontes-Cal TCM; Mattos RT; Medeiros NI; Pinto BF; Belchior-Bezerra M; Roque-Souza B; Dutra WO; Ferrari TCA; Vidigal PVT; Faria LC; Couto CA; Gomes JAS
Front Immunol; 2021; 12():708959. PubMed ID: 34447378
[TBL] [Abstract][Full Text] [Related]
34. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
Kado A; Tsutsumi T; Yotsuyanagi H; Ikeuchi K; Okushin K; Moriya K; Koike K; Fujishiro M
J Gastroenterol; 2023 Dec; 58(12):1237-1251. PubMed ID: 37707595
[TBL] [Abstract][Full Text] [Related]
36. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
[TBL] [Abstract][Full Text] [Related]
37. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
Gunn NT; Shiffman ML
Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
[TBL] [Abstract][Full Text] [Related]
38. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
[TBL] [Abstract][Full Text] [Related]
39. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease.
Singh H; Pollock R; Uhanova J; Kryger M; Hawkins K; Minuk GY
Dig Dis Sci; 2005 Dec; 50(12):2338-43. PubMed ID: 16416185
[TBL] [Abstract][Full Text] [Related]
40. Association of polymorphisms of adiponectin gene promoter-11377C/G, glutathione peroxidase-1 gene C594T, and cigarette smoking in nonalcoholic fatty liver disease.
Zhang CX; Guo LK; Qin YM; Li GY
J Chin Med Assoc; 2016 Apr; 79(4):195-204. PubMed ID: 26897098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
